Floatz logo

Belinostat

Dose Escalation: Solid Tumors

Valerio TherapeuticsSmall moleculePhase 1/2Dormant
CCC
52/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Dose Escalation: Solid Tumors cohort.

Asset / SponsorPhaseRating
Inno-206
Valerio Therapeutics
Phase 1/2CCC

Same molecule, other indications

Belinostat is also rated in:

HIV InfectionsDormant
BB
Indicative ·
67 / 100
View asset →
ovarian carcinomaDormant
BB
Indicative ·
65 / 100
View asset →
diffuse large B-cell lymphomaDormant
B
Indicative ·
63 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →